ELI LILLY & Co is 203.7x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($1.070 T vs $5.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APLS | LLY |
|---|---|---|
| Market cap | $5.25 B | $1.070 T |
| US-listed rank | #1357 | #10 |
| Revenue (latest FY) | $1.00B | $65.18B |
| Net income (latest FY) | $22.39M | $20.64B |
| Net margin | 2.2% | 31.7% |
| P/E (trailing FY) | 234.6 | 51.8 |
| SEC filings | 1,217 | 989 |
ELI LILLY & Co is 203.7x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($1.070 T vs $5.25 B).
In their latest fiscal years, Apellis Pharmaceuticals, Inc. reported $1.00B in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Apellis Pharmaceuticals, Inc. and ELI LILLY & Co, or browse the full rankings.